JP2016525563A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525563A5
JP2016525563A5 JP2016530548A JP2016530548A JP2016525563A5 JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5 JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
therapeutic agent
halogen atom
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6453877B2 (ja
JP2016525563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/066629 external-priority patent/WO2015014998A1/en
Publication of JP2016525563A publication Critical patent/JP2016525563A/ja
Publication of JP2016525563A5 publication Critical patent/JP2016525563A5/ja
Application granted granted Critical
Publication of JP6453877B2 publication Critical patent/JP6453877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016530548A 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤 Expired - Fee Related JP6453877B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861291P 2013-08-01 2013-08-01
US61/861,291 2013-08-01
US201361863118P 2013-08-07 2013-08-07
US61/863,118 2013-08-07
PCT/EP2014/066629 WO2015014998A1 (en) 2013-08-01 2014-08-01 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2016525563A JP2016525563A (ja) 2016-08-25
JP2016525563A5 true JP2016525563A5 (enExample) 2017-09-14
JP6453877B2 JP6453877B2 (ja) 2019-01-16

Family

ID=51260882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530548A Expired - Fee Related JP6453877B2 (ja) 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤

Country Status (6)

Country Link
US (1) US9795612B2 (enExample)
EP (1) EP3027194A1 (enExample)
JP (1) JP6453877B2 (enExample)
KR (1) KR20160036591A (enExample)
CN (1) CN106029077A (enExample)
WO (1) WO2015014998A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
RU2016146099A (ru) * 2014-05-02 2018-06-05 Онкоэтикс Гмбх Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений
JP2017529332A (ja) * 2014-08-28 2017-10-05 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法
WO2016156905A1 (en) * 2015-04-03 2016-10-06 Oncoethix Gmbh Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
EP3658123A4 (en) * 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
CN117794525A (zh) 2021-06-08 2024-03-29 加利福尼亚大学董事会 抗癌化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69717160T2 (de) * 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
AU2006270187A1 (en) * 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
US20100120788A1 (en) * 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
KR101600634B1 (ko) * 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP2376495A4 (en) * 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
MX2014015986A (es) * 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
EP2900221B1 (en) 2012-09-28 2019-03-06 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法

Similar Documents

Publication Publication Date Title
JP2016525563A5 (enExample)
JP2015531747A5 (enExample)
JP2016529246A5 (enExample)
JP2016538310A5 (enExample)
JP2017517579A5 (enExample)
RU2015101106A (ru) Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
JP2016523270A5 (enExample)
JP2017511357A5 (enExample)
JP2016507581A5 (enExample)
RU2015133528A (ru) Замещенные полициклические пиразольные ингибиторы киназной активности и их применение
JP2013540712A5 (enExample)
JP2021501208A5 (enExample)
JP2014518544A5 (enExample)
JP2011527667A5 (enExample)
JP2014514317A5 (enExample)
JP2017529332A5 (enExample)
JP2015509536A5 (enExample)
JP2016501185A5 (enExample)
JP2016531868A5 (enExample)
JP2017519727A5 (enExample)
JP2015504091A5 (enExample)
JP2017514909A5 (enExample)
JP2019512535A5 (enExample)
JP2015537017A5 (enExample)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用